Skye Bioscience, Common Stock Investor Sentiment

SKYE Stock  USD 2.86  0.15  4.98%   
About 67% of Skye Bioscience,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that many traders are alarmed. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
  

Skye Bioscience, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three weeks ago at thelincolnianonline.com         
Kaitlyn Arsenault Sells 43,206 Shares of Skye Bioscience, Inc. Stock
news
over three weeks ago at investing.com         
Skye Bioscience chief development officer sells shares worth 97,721
Investing News at Macroaxis
over three weeks ago at telegraph.co.uk         
Disposition of 19489 shares by Diep Tuan Tu of Skye Bioscience, at 4.99 subject to Rule 16b-3
news
over a month ago at gurufocus.com         
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Disposition of 86244 shares by Grayson Paul A. of Skye Bioscience, at 4.99 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3
Macroaxis News
over a month ago at globenewswire.com         
Skye Bioscience Surpasses 50 percent Patient Enrollment in Phase 2 Obesity Study of Differentiated C...
Macroaxis News: globenewswire.com
over a month ago at investing.com         
Skye Biosciences SWOT analysis nimacimabs potential in obesity stock market
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Yahoo News
over a month ago at seekingalpha.com         
Skye Bioscience GAAP EPS of -0.10 beats by 0.15
seekingalpha News
over a month ago at seekingalpha.com         
Skye Bioscience Q3 2024 Earnings Preview
seekingalpha News
over a month ago at finance.yahoo.com         
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant We...
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Skye Bioscience to Announce Third Quarter 2024 Results
Yahoo News
over a month ago at thelincolnianonline.com         
Skye Bioscience, Inc. Short Interest Up 17.4 percent in October
news
Far too much social signal, news, headlines, and media speculation about Skye Bioscience, that are available to investors today. That information is available publicly through Skye media outlets and privately through word of mouth or via Skye internal channels. However, regardless of the origin, that massive amount of Skye data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Skye Bioscience, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Skye Bioscience, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Skye Bioscience,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Skye Bioscience, alpha.

Skye Bioscience, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3
10/28/2024
2
Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3
11/01/2024
3
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
11/07/2024
4
Skye Bioscience Surpasses 50 percent Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
11/14/2024
5
Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3
11/15/2024
6
Disposition of 86244 shares by Grayson Paul A. of Skye Bioscience, at 4.99 subject to Rule 16b-3
11/18/2024
7
Skye Bioscience chief development officer sells shares worth 97,721
11/20/2024
8
British Design Firm Forecasts 2025 Color Trends
11/21/2024
9
Callous coward Finlay MacDonald jailed for life after murdering his brother-in-law
11/29/2024
10
Insider Trading
12/09/2024
11
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
12/19/2024

Complementary Tools for Skye Stock analysis

When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years